Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 3 | 2017

Login to access report north_east
Contact sales account_box

Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/Genentech’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity for Venclexta.

What you will learn in this content:

  • What is U.S. hematologist-oncologists’ awareness of and familiarity with Venclexta, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Venclexta, what are the reasons for prescribing, and how satisfied are they with Venclexta?
  • What promotional messages and activities are Roche/Genentech employing in support of the Venclexta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Venclexta tracking compared with other recent first-in-class product launches in the oncology market?

Methodology: ~75-100 U.S. hematologist-oncologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.

Related reports: Venclexta Launch Tracking (US) Wave 1, Venclexta Launch Tracking (US) Wave 2, Derzalex/Emplicity Launch Tracking (US) Wave 3

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
north_east
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
north_east
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
north_east
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
north_east
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east